ASCO GI 2021 | FRESCO-2: Phase III study of fruquintinib in patients with mCRC

Arvind Dasari, MD, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses FRESCO-2 (NCT04322539), an ongoing global Phase III study evaluating the efficacy and safety of fruquintinib in patients with metastatic colorectal cancer (mCRC). Fruquintinib is an oral anti-VEGFR tyrosine kinase inhibitor approved in China for use in mCRC, and currently being investigated in patients with mCRC who have progressed from previous standard approved therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).